Pancreatic Cancer Research

ResearcherShenzhen UniversityNo recent work listed

Peng Gong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1943-1014; OpenAlex author ID A5101920891, A5101920892. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers

Papers 9

  1. Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer. Co-author DOI 10.1016/j.drup.2023.101005↗
  2. Combined chemotherapy based on bioactive black phosphorus for pancreatic cancer therapy. Co-author DOI 10.1016/j.jconrel.2022.12.054↗
  3. Identification of a New m6A Regulator-Related Methylation Signature for Predicting the Prognosis and Immune Microenvironment of Patients with Pancreatic Cancer. Last author DOI 10.1155/2023/5565054↗
  4. Development of a Transcription Factor-Based Prognostic Model for Predicting the Immune Status and Outcome in Pancreatic Adenocarcinoma. Last author DOI 10.1155/2022/4946020↗
  5. PIK3CB is involved in metastasis through the regulation of cell adhesion to collagen I in pancreatic cancer. Co-author DOI 10.1016/j.jare.2021.02.002↗
  6. The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jare.2020.03.009↗
  7. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer. Co-author DOI 10.7150/thno.47001↗
  8. LW6 enhances chemosensitivity to gemcitabine and inhibits autophagic flux in pancreatic cancer. Co-author DOI 10.1016/j.jare.2019.04.006↗
  9. Pancreaticoduodenectomy is justified in a subset of elderly patients with pancreatic ductal adenocarcinoma: A population-based retrospective cohort study of 4,… Co-author DOI 10.1016/j.ijsu.2018.03.054↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianbin Zhang · 8 shared papers, 2018–2023 · strength 1.17
  2. Masafumi Nakamura · 2 shared papers, 2020–2021 · strength 0.21
  3. Biao Zheng · 2 shared papers, 2020–2021 · strength 0.21
  4. Kenoki Ohuchida · 2 shared papers, 2020–2021 · strength 0.21
  5. Jianhua Qu · 2 shared papers, 2020–2021 · strength 0.21
  6. Tianle Zou · 1 shared paper, 2023 · strength 0.20
  7. Wenhua Zhou · 1 shared paper, 2023 · strength 0.19
  8. Shengyong Geng · 1 shared paper, 2023 · strength 0.19
  9. Peng Liu · 2 shared papers, 2018–2020 · strength 0.18
  10. Milad Ashrafizadeh · 1 shared paper, 2023 · strength 0.15
  11. Weiguang Li · 1 shared paper, 2023 · strength 0.15
  12. Wei Zhang · 1 shared paper, 2023 · strength 0.15
  13. Jiahui Yuan · 1 shared paper, 2023 · strength 0.15
  14. Dietmar Zechner · 1 shared paper, 2019 · strength 0.11
  15. Brigitte Vollmar · 1 shared paper, 2019 · strength 0.11
  16. Simone Kumstel · 1 shared paper, 2019 · strength 0.11
  17. Hailong Chen · 1 shared paper, 2020 · strength 0.11
  18. Caiming Xu · 1 shared paper, 2020 · strength 0.11
  19. Guixin Zhang · 1 shared paper, 2020 · strength 0.11
  20. Daiki Eguchi · 1 shared paper, 2020 · strength 0.09
  21. Zilong Yan · 1 shared paper, 2020 · strength 0.09
  22. Takao Ohtsuka · 1 shared paper, 2020 · strength 0.09
  23. Lili Lu · 1 shared paper, 2018 · strength 0.09
  24. Li Ma · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.